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dialysis in France between 1997 and 2002.
Background. In 1997, 0.38% of dialysis patients in France
were infected by human immunodeficiency virus (HIV). No
prevalence data were available in France since the widespread
introduction of highly active antiretroviral therapy.
Methods. This was a cross-sectional epidemiologic survey. A
questionnaire was sent to all French dialysis centers in July 2002.
The centers that did not respond were sent 3 additional mailing
reminders. Finally, the nonresponding centers were called early
in 2004.
Results. Of the 27,577 patients on hemodialysis and 587 pa-
tients on peritoneal dialysis, 190 patients (0.67%) were infected
by HIV. HIV-associated nephropathy was the cause of renal fail-
ure in 39.8% patients. Mean age was 44.6 ± 10.9 years, the mean
duration of dialysis was 4.9 ± 5.9 years, the mean known dura-
tion of HIV infection was 8.9 ± 5.6 years. Eighty-two percent of
patients received antiretroviral therapy (ART). Fifty-eight per-
cent of ART-treated patients had an undetectable HIV plasma
viral load with a median CD4+ T-cell count 303/mm3.
Conclusion. The prevalence of HIV infection among French
dialysis patients was 0.67% in late 2002, a 79% increase since
1997. Possible reasons for this large increase include increased
access to dialysis, better general status of HIV dialysis patients,
and increasing proportion of patients originating from Africa
and the Caribbean. The current efficacy of ART makes renal
transplantation a realistic option for these young patients.
Human immunodeficiency virus (HIV) infection can
cause end-stage renal disease (ESRD) through both
HIV-associated nephropathy (HIVAN) and antimicro-
bial drug toxicity, or may be a comorbid condition associ-
ated in dialysis patients. In the United States, HIV renal
diseases represent the third cause of ESRD in African
Americans between 24 and 60 years [1].
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In the last 10 years, the survival of HIV-infected pa-
tients has spectacularly improved [2, 3]. In the United
States dialyzed HIV (HID) population, a recent epidemi-
ologic study also showed a marked increase in survival
since 1990, with the major improvement occurring since
1997 [4]. This change could potentially reflect the use of
the highly active antiretroviral therapy (HAART) [4, 5].
The HID patients represented 1.3% of all dialysis pa-
tients in the United States in 1997, and 1.5% in 2000 [6,
7]. The cause of end-stage renal disease in such patients is
listed as HIV-associated nephropathy in 70% to 99% of
cases according to the studies, but renal biopsies are often
lacking [1, 4]. Eighty-three to 89% of these patients are
African Americans [1, 4]. Eighty-eight to 94% were on
maintenance hemodialysis, and 6% to 12% on peritoneal
dialysis [1, 8].
In France, no registry has been available until now for
hemodialysis patients, and one has been in progress since
2003 for HIV patients. No epidemiologic data on HID
patients have been recorded since 1997 in France. It is
likely that, as in the United States, the characteristics of
such patients have changed, notably with the advent of
HAART [9, 10].
In order to determine the clinical characteristics of
HID patients in France since HAART, we conducted a
cross-sectional epidemiologic study in all dialysis centers
in France at the end of 2002, 5 years after the last such
study.
METHODS
From July 2002 to March 2004, a questionnaire was
first sent to the physicians of all 795 French dialysis
centers (public and private), requesting information on
the total number of dialysis patients and the number of
HID patients. Nonresponding centers were sent 3 mail-
ing reminders, in September 2002, February 2003, and
September 2003, and the few nonresponding centers were
called at the beginning of 2004. A separate question-
naire on each HIV-infected patient was sent to obtain:
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demographic data, renal diagnosis (clinical or by kidney
biopsy), durations of dialysis, and HIV infection (date
of the first positive HIV serology), mode of HIV trans-
mission, or risk factors, last HIV plasma viral load, and
CD4 T-cell count values, dialysis technique, current an-
tiretroviral treatment (ART), and hepatitis C coinfection
(HCV).
In all dialysis centers in France, the HIV and HCV sta-
tus of each patient is determined at the time of the begin-
ning of dialysis and once or twice per year. Opportunistic
infections are determined according to the CDC 93 clas-
sification. HIV plasma viral load and CD4 T-cell count
values were those determined routinely in each center.
We did not ask about transplanted HIV patients, who are
most often treated in separate transplantation centers.
A descriptive analysis was performed using Excel
software (Microsoft, Redmond, WA, USA).
RESULTS
In April 2004, the response rate to the center question-
naire was 100%. The overall rate of complete responses
on HIV patients was 94.7%.
At the end of 2002, there were 190 HID patients
in 86 different centers among 28,164 living patients
with ESRD on maintenance dialysis, thus representing
a prevalence rate of 0.67%. Three HIV-infected patients
were on peritoneal dialysis (0.51% of peritoneal dialy-
sis patients), while 187 patients were on hemodialysis
(0.68% of hemodialysis patients). At the end of 1997,
there were 82 patients in dialysis. Thus, we can estimate
the incidence: 108 patients more in 5 years, so 21.6% in-
cidence rate.
Data were complete for 180 HIV-infected patients, in-
cluding 50 women (27.8%) and 130 men (72.2%). The
mean age was 44.6 ± 10.9 years. One hundred forty pa-
tients (60%) were black. Their geographic origin was sub-
Saharan Africa in 68 cases (37.8%), metropolitan France
or another European country in 44 cases (24.5%), French
Caribbean in 40 cases (22.2%), South Mediterranean in
9 cases (5.0%), Japan in 1 (0.6%), Haiti in 7 (3.8%), and
not reported in 11 cases (6.1%). One hundred seventeen
patients (61.6%) were living in the Paris area, and 20 pa-
tients (10.5%) were living in the French Caribbean and
Guyana.
The mean duration of dialysis was 4.9 ± 5.9 years
(median 3.0 years [0–29]) (Table 1). The main causes
of ESRD reported by the nephrologist were HIVAN
(39.8%). The other causes were: non HIVAN but HIV
related (2.3%), diabetes (8.8%), glomerulonephritis in-
cluding IgA nephropathy (9.3%), nephroangiosclerosis
(7.0%), renal and ureteral malformations (5.8%), in-
terstitial nephropathy (4.7%), and thrombotic microan-
giopathy (4.1%) (Table 2). Fifty-seven percent of these
patients had a biopsy-proven diagnosis.
Table 1. Demographic data on HIV-infected ESRD patients:
Changes between 1997 and 2002
1997a 2002
Number 82 190
Hemodialysis/peritoneal dialysis 79/3 187/3
Men 61 130
Blacks 49 114
Mean age years 41.8 44.6 ± 5.9
Mean dialysis duration years 5.1 4.9 ± 5.9
Mean HIV duration years 8 ± 3.6 8.9 ± 5.6
HIVAN N/% 23/27% 68/39.8%
aPoignet et al, Nephrologie 20:159–163, 1999.
Table 2. Causes of ESRD (N = 171)
(N/%)
HIVAN 68/39.8%
Non-HIVAN HIV-related 4/2.3%
Glomerulonephritis including IgA nephropathy 16/9.3%
Diabetes 15/8.8%
Nephroangiosclerosis 12/7.0%
Malformation/reflux 10/5.8%
Interstitial nephropathy 8/4.7%
Thrombotic microangiopathy 7/4.1%
Focal and segmental sclerosis 5/2.9%
Cryoglobulinemia 2/1.2%
Membranous glomerulopathy 2/1.2%
Rapidly progressive glomerulonephritis 1/0.6%
Lupus nephropathy 1/0.6%
Chronic graft rejection 1/0.6%
Other and unknown 19/11.1%
HIV infection was documented 8.85 ± 5.62 years be-
fore the study (median 8.0 years [0–29 years]). For 18 pa-
tients, HIV was discovered after the beginning of dialysis.
For the other ones, the HIV infection was documented
5.01 ± 4.69 years before initiation of dialysis (median 4
years [0–17 years]). Sixty-one percent underwent oppor-
tunistic infections (35.2%). Sixty-nine patients (36.3%)
were probably infected by sexual exposure. Twenty-six
(15.0%) patients had a history of intravenous drug use.
Nineteen (11.0%) patients were infected by blood trans-
fusion, and 2 (1.2%) by renal graft. One hundred fifteen
(63.8%) came from countries with chronic endemia. Scar-
ification was incriminated in 1 case (0.6%). Forty-four
patients (25.1%) were coinfected by HCV.
One hundred forty-two patients (82.5%) were on an-
tiretroviral therapy (ART) at the time of dialysis, with a
median of 3 drugs in combination [0–6]. Only 1 patient
(0.7%) received a single drug, while 14 (9.8%) were on 2
drugs, 97 (68.4%) on 3 drugs, 26 (18.3%) on 4 drugs, and
4 (2.8%) were on 5 or more drugs (Table 3).
HIV plasma viral load was undetectable (<50 cp/mL
in the bDNA Bayer test, or <20 cp/mL in the Roche
PCR test) in 83 patients (58.4% HAART among ESRD
patients). The median CD4 T-cell count was 336/mm3 [2–
1000] (Table 4).
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Table 3. Antiretroviral treatment (N = 141)
French
Literature population %
ART (no definition) Abbott 2003: 61% 91.6%
Szczech
2003: 70.7% alive patients
HAART definition
Combination ART ≥2 Abbott 2003: 25% 90%
Combination ART ≥3 Rodriguez 2003: 33% 54%
including at least 1 PI
Combination ART ≥3 Ahuja 2000: 68% 75%
Combination including 83%
NRTI (overall)
Combination including 23.4%
NNRTI (overall)
Single drug regimen 0.5%
Double drug regimen 8.1%
Triple drug regimen 57.0%
Four drug regimen 15.7%
Five drug regimen 1.7%
Six drug regimen 0.5%
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non nucleoside
reverse transcriptase inhibitor; PI, protease inhibitor.
Table 4. HIV disease status (N = 172)
Patients Patients not
receiving ART receiving ART
142/82.5% 30/17.5%
Number of ART drugs mean ± SE 3 [0–6] 0
Median CD4 count/mm3 303 [2–1000] 367 [10–907]
Median viral load log 2.3 [0–5.8] 2.8 [1.3–5.2]
Undetectable viral load N/% 58.3% 29.6%
DISCUSSION
We present here the first cross-sectional study con-
ducted in France since the widespread use of HAART
on ESRD HIV-infected dialysis patients. France still does
not have a national registry available for dialyzed pa-
tients, and did not have one until 2003 for HIV patients.
But the 100% response rate by French dialysis centers is
comparable to a registry study, and implies that nephrol-
ogists are aware of this specific situation.
This study shows a 79% prevalence rise of HIV patients
(from 0.38% to 0.67%) among French dialysis patients
since 1997 (22 new patients per year, thus a 21.6% esti-
mated incidence rate), an incidence rate largely higher
that of non-HIV dialysis patients in France (estimated
incidence rate between 4% and 8% per year, according
to recent series) [9, 11, 12].
First, this prevalence increase could be related to an
important number of new HIV ESRD patients. HAART
use for renal failure patients was delayed compared to
the patients without renal symptoms because physicians
had been reluctant to use antiretroviral drugs in these pa-
tients prior to 1997 [1, 5, 13]. HAART has clearly changed
the profile of HIV patients, improving dramatically their
general status and survival, allowing them to live long
enough to reach ESRD and access to dialysis [6, 14]. In
the United States, as well as in France, maintenance dialy-
sis therapy was often discussed for HIV-infected patients
before 1995 because of the high mortality rate in these pa-
tients, and their bad general status at the time of dialysis
beginning [4, 5, 6, 15–18]. Moreover, just a small number
of dialysis centers accepted HIV patients. Since HAART,
between 1985 and 1999, the proportion of dialysis centers
caring for HIV-infected patients rose from 11% to 39%
in the United States [6, 7, 19]. In France, there were HIV
patients in 42 different centers in 1997, and in 2002 there
were 86 [9].
Second, the larger utilization of HAART in HID
patients, together with management and prophylaxis
against opportunistic infections and technical advance in
dialysis, has probably improved the survival of French pa-
tients. In France, 82.5% of HID population was treated
by ART, which may have increased survival similar to
the increase in survival seen in the United States non-
ESRD HIV population [4, 19, 20]. However, we did not
have data concerning the survival of these patients. We
could also not use dialysis duration as reflection of sur-
vival with ESRD because the important number of new
patients decreased the mean.
Third, this prevalence increase could be due to an in-
creased incidence of HIV infection in the French gen-
eral population. Unfortunately, national registry of new
cases of HIV infection was only started in January 2003,
while previous epidemiologic surveys were based solely
on AIDS cases. However, as in other western European
countries, the prevalence and incidence of HIV infec-
tion is considered to have been stable in the last 5 years,
with a continuous decrease in AIDS cases [21]. But in
France, significant numbers of immigrants come from
sub-Saharan Africa (French-speaking countries in west
and central Africa) and from the Caribbean, where the
HIV epidemic is raging. The proportion of patients orig-
inating from Africa and the French Caribbean in the
French national AIDS survey has been growing continu-
ously since 1998 (Fig. 1) [21, 22]. In addition, African and
Caribbean patients are known to develop HIVAN more
frequently than Caucasians. And, as shown in Figure 1,
the proportion of these patients in the HID population is
increasing yearly. Thus, it is possible that although the to-
tal number of HIV patients was not increasing in France,
there was a higher proportion of high-risk patients for
HIVAN and HID.
Thus, the huge prevalence increase of HIV-infected
dialysis patients in France may be partly related to an
increased number of new patients because of improve-
ment of access to dialysis, and better general status of
HIV-infected ESRD patients before and during dialysis
therapy, but also because of the rise in immigration from
African and Caribbean countries with active epidemics.
Compared to the previous study in 1997, the geo-
graphic distribution of French HID patients has not
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Fig. 1. Year of dialysis beginning according to the geographic origin. Large increase of patients from endemic countries.
significantly changed, with a marked concentration in the
Paris area (56.2% in 1997 vs. 61.6% in 2002) and in the
French Caribbean (9.3% in 1997 vs. 10.5% in 2002). These
results correlate with the epidemiology of AIDS (59% of
new AIDS cases were found in the Paris area in 2002).
Similarly, in the United States, the HIV prevalence has
the same geographic repartition than the HIV repartition
[14, 21].
Some epidemiologic differences appear between the
French and the United States HID population. The
United States HID population is essentially black, with
89% to 92% African American patients, while there are
63.8% African and Caribbean patients in France. Be-
cause HIVAN almost exclusively affects African Amer-
icans or Caribbean patients, HIVAN is the cause listed
of ESRD in 66% to 99% of HID patients in the United
States, compared to only 39.9% in France [1, 4, 7, 13, 23].
HCV coinfection also affected 68% of United States HID
patients compared to only 25.1% of patients in France
[1, 8, 13]. Sixty-eight percent of United States HID pa-
tients are intravenous drug users (a strong risk factor for
noncompliance and death in ESRD population), as com-
pared to 15.0% in France. All of these differences let us
postulate that the HID United States population has a
worse socioeconomic status than the HIV French popu-
lation. Indeed, it has been shown that worse economic
status correlates with poorer health care, reduced access
to dialysis, and to ART [24, 25]. Moreover, HIVAN, HCV
coinfection, and intravenous drug use have demonstrated
as strong risk factors of death in ESRD population [14,
19, 25]. Taken together, these differences could in part
explain the lower rise in HID prevalence in the United
States compared to France: 15% increasing in 3 years ver-
sus 79% in 6 years in France [1.3% in 1997 and 1.5% in
2000 in United States (no significant change)] [6, 13].
Another difference appears in ESRD etiologies be-
tween the United States and French populations.
Hemolytic and uremic syndrome (HUS) represents 4.1%
of the etiology of chronic renal failure in the French HID
population. It is much more common than in the United
States, in whom the prevalence seems to be less than 2%
[1, 6, 26]. However, our results are in keeping with several
surveys done in France. In one study, HUS accounted for
34% of acute renal failure among HIV patients, and in
another one, HIV accounted for 33% of HUS patients
[27, 28]. In an Italian study, there was 1.4% of HUS in
HIV population before HARRT era [29].
A difference in the viral genotype may account for the
differences in the etiologies of ESRD in HIV patients be-
tween the United States and Europe [6, 30]. A difference
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between biopsy policies could also explain this difference,
which may account for overestimation of the frequency
of HIVAN in the United States [1]. Fifty-seven percent
of French patients had a biopsy-proven diagnosis, against
45.9% in Szczech’s survey, and only 28% in Rodriguez’s
one [1, 13]. Interestingly, in Szczech’s study, the repar-
tition between diagnoses differs between the group of
patients who underwent a biopsy and the group who did
not.
Finally, we tried to compare treatment regimens be-
tween French and United States patients (Table 3). How-
ever, this comparison is difficult for several reasons. First,
the definition of HAART varies between reports. Second,
some surveys analyze treatment regimens at the start of
dialysis, while others do so during dialysis therapy. Finally,
in all surveys, including ours, there are substantial vari-
ations in dosing regimens for ART medications among
patients, despite newly available guidelines in ESRD pa-
tients. This variation often results in the over- or under-
prescription of drugs, a situation resulting in suboptimal
use of ART in ESRD patients [1, 13, 31]. The definition
aside, ART seems more frequently used in France than in
the United States (Table 3). Despite considerable varia-
tion of dosing regimens, including patients receiving only
1 drug, the response of HID patients to ART appears to
be good. Namely, 58.3% of treated patients had an un-
detectable viral load in contrast to only 29.6% in the un-
treated group (Table 4). One possible explanation for the
differences in ART prescriptions between France and the
United States could be the cost of ART and the health
insurance system. In France, all haemodialysis patients
have free access to medications, including HAART. In
the United States, patients who do not have Medicare or
Medicaid, or are partially insured, can receive antiretro-
viral drugs through ADAP (AIDS Drug Assistance Pro-
grams). The ADP is funded by each state, and the level of
coverage is, therefore, highly variable. One registry sur-
vey noted that 18.7% of ESRD HIVAN patients have
no medical insurance, whereas all but 6.3% of ESRD pa-
tients have coverage [25]. Moreover, patients of African
American origin, who constitute a large proportion of
HID patients in the United States population, are more
likely to be in the lower end of the socioeconomic spec-
trum, a fact that could reduce access to both renal re-
placement and antiretroviral therapy [4, 25, 32].
Finally, we found that in France, as in the United
States, there is an increasing young and relatively healthy
HIV, ESRD population who could be suitable for re-
nal transplantation. Immunovirologic response of these
patients to HAART is satisfactory. Beneficial interac-
tions between calcineurin inhibitors or mycophenolate
mofetil and HIV infection and antiretroviral therapy on
the other hand, have been reported [9, 33–36]. Until re-
cently, HIV infection was considered a contraindication
to renal transplantation. To our knowledge, few patients
have been transplanted in France, while there have been
more transplantations in the United States, with good re-
sults on graft survival, patient survival, and absence of
HIV progression (1, 37–39, abstract; De Vera ME et al,
Am J Transplant 2(Suppl 3):139a, 2002).
LIMITATIONS
In France, compared with the United States, we do not
dispose of national registry for hemodialysis patients. A
registry for HIV just started to be constituted in 2003.
Thus, it is difficult to analyze epidemiologic data in French
patients. This survey allowed creating a HID registry that
would be continued. After this first cross-sectional survey,
we have decided to use this database for more specific
studies. The first is going to evaluate drug regimen and
the impact of dose variations on drug efficiency and drug
toxicity.
CONCLUSION
This survey shows that the prevalence of HIV infec-
tion among French dialysis patients has been increasing
to 0.67% in late 2002. We explain it by longer survival
of HIV patients, and in consequences in HID patients,
and by an increasing proportion of HIV-infected patients
originating from Africa and the Caribbean. There is now
in France, as in the United States, an increasing popula-
tion of HID young patients, for whom renal transplanta-
tion needs to be developed.
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